Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)

Official Summary

The goal of this clinical trial is to To demonstrate the Safety and Efficacy of dcLVA Surgery for the Treatment of Alzheimer's Disease. Patients who meet the inclusion and exclusion criteria and consent to participate will be randomly assigned to either the experimental group (receiving dcLVA surgery plus standard medication) or the control group (receiving standard medication alone) Participants will: Undergo cognitive assessment and brain MRI assessment; Undergo a lumbar puncture; Undergo an injection of 20ml of gadodiamide contrast agent at a concentration of 0.5 mmol/L (1ml gadodiamide: 20ml 0.9% saline). Primary Outcome Measures: The change in the sum of Clinical Dementia Rating Scale (CDR) scores at 12-month in relative to baseline

Study Design

• Study Type: INTERVENTIONAL
• Allocation: RANDOMIZED
• Model: SINGLE_GROUP
• Masking: NONE
• Enrollment: 60 participants

Study Arms

• experimental group (EXPERIMENTAL)
  receiving dcLVA surgery plus standard medication
• control group (ACTIVE_COMPARATOR)
  receiving standard medication alone

Interventions

• PROCEDURE: Deep Cervical lymphatlc-Venous Anastomosis Surgery — Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal o
• DRUG: Lecanemab — The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.

Primary Outcomes

• The rate of change in the total score of the Clinical Dementia Rating Scale (Time Frame: baseline,7 days post-surgery,3-month,6-month and 12-month)

Eligibility Criteria

Inclusion Criteria:

* Diagnosed as an AD patient according to biological markers and clinical symptoms;
* Over 35 years old and with an MMSE or MOCA score ≤ 26;
* The patient or family member has signed an informed consent form.

Exclusion Criteria:

* Inability to cooperate with lumbar puncture;
* Cognitive impairment due to neurological infections (e.g., HIV, neurosyphilis, autoimmune encephalitis) or systemic diseases (e.g., diabetes, thyroid dysfunction);
* Significant organ dysfunction (heart, lung, liver, kidney);
* Coagulation disorders or contraindications to surgery;
* Inability to fully cooperate with follow-up visits.

Trial Locations

• Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

More Alzheimer's Disease Trials

View all Alzheimer's Disease clinical trials